| http://www.w3.org/ns/prov#value | - Company: PRESAGE BIOSCIENCES, INC. Agency/Program/Year/Phase: HHS / STTR / 2010 / 1Abstract: DESCRIPTION (provided by applicant): Over 90% of cancer patients that enroll in Phase I or II clinical trials experience no benefit from the experimental therapies, yet are exposed to drug toxicity and other challenges related to treatment.
|
